Contact Information: Contact: Jeffrey J. Kraws/Karen B. Goldfarb Crystal Research Associates, LLC P: (609) 306-2274 F: (609) 395-9339
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corp.
| Source: Crystal Research Associates, LLC
NEW YORK, NY--(Marketwire - January 25, 2010) - Crystal Research Associates, LLC announced
today that it has issued an Executive Informational Overview® (EIO®) on
CEL-SCI Corp. (NYSE Amex : CVM ). The full 64-page report can be found at
www.crystalra.com.
CEL-SCI Corp. ("CEL-SCI" or "the Company") develops cancer and infectious
disease products that empower immune system defenses. CEL-SCI is organized
into three business units: (1) Multikine®, a non-toxic immunotherapy with
Orphan Drug status that is poised to enter a global, open-label Phase III
trial for advanced primary head and neck cancer; (2) Treatment Vaccines,
which includes an H1N1 (pandemic influenza) treatment that entered a
clinical study in November 2009 as well as a preclinical treatment vaccine
for rheumatoid arthritis (RA); and (3) Contract Manufacturing Services
using the Company's new manufacturing facility to generate near-term
revenue.
CEL-SCI's lead candidate, Multikine®, is a patented mix of biologically
active natural cytokines and is the first of a new class of cancer
immunotherapy drugs called immune simulators, which are designed to closely
mimic the body's natural immune system. Unlike other immunotherapies,
Multikine® is multi-targeted -- it activates multiple cellular components
of the immune system to fight cancer -- and is administered to patients
before any other treatment, when the immune system is strongest (namely
before the patient receives surgery, chemotherapy, or radiotherapy). It has
been shown to kill roughly 50% of tumor cells before the standard of care
commences and renders residual cancer cells that survive treatment more
susceptible to radiation and chemotherapy. In over 200 patients treated to
date, Multikine® has been reported to be safe and well tolerated,
improving patients' overall survival by 33% at a median of 3.5 years
following surgery versus that attained using the standard of care without
Multikine® (surgery plus radiation or surgery plus combined
chemoradiotherapy).
CEL-SCI plans to begin the Phase III trial of Multikine® at multiple
centers in North America, the European Union (EU), South America, and Asia
in the summer of 2010. The Company believes that a positive Phase III
outcome could enable Multikine® to be routinely included as part of the
standard of care for all advanced primary head and neck cancer patients.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that
provides institutional-quality, fee-based research to small and mid-cap
companies. Crystal Research Associates' unique and novel product, the
Executive Informational Overview® (EIO®), is free of investment ratings,
target prices, and forward-looking financial models. The EIO® presents a
crystal clear, detailed report on a company (public or private) in a manner
that is easily understood by the Wall Street financial community. The EIO®
details a company's product/technology/service offerings, market size(s),
key intellectual property, leadership, growth strategy, competition, risks,
financial statements, key events, and other such fundamental information.
Crystal Research Associates has offices in New York City, West Palm Beach,
Montréal, and Toronto. Crystal Research Associates has been compensated by
the Company in cash of sixty thousand dollars and two hundred thousand
Options/Warrants to purchase CEL-SCI stock for its services in creating and
updating the base report, for updates, and for printing costs.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating
results, potential applications of the Company's technology, opportunities
for the Company, and any other statements about the future expectations,
beliefs, goals, plans, or prospects expressed constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Any statements that are not statements of historical fact
(including statements containing the words "will," "believes," "plans,"
"anticipates," "expects," "estimates," and similar expressions) should also
be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements
including, limited operating history, need for future capital, and economic
conditions generally. Additional information on potential factors that
could affect results and other risks and uncertainties are detailed from
time to time in the Company's periodic reports, including forms filed with
the SEC.
These statements, and other forward-looking statements, are not guarantees
of future performance and involve risks and uncertainties. Crystal Research
Associates assumes no obligation to update any of the forward-looking
statements in this release.